Sound waves may help deliver brain tumor drug
NCT ID NCT04446416
First seen Apr 23, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This pilot study tested a device called NaviFUS that uses focused ultrasound to temporarily open the blood-brain barrier, combined with the drug bevacizumab (Avastin), in 6 patients with recurrent glioblastoma (a type of brain cancer). The goal was to see if the combination is safe and can slow tumor growth. Patients received the treatment after standard therapies had failed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Linkou Chang Gung Memorial Hospital
Taoyuan City, 33305, Taiwan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bevacizumab (Avastin) combined with focused ultrasound (NaviFUS system)
What this could lead to
If successful, this approach could offer a new way to deliver drugs to brain tumors by temporarily opening the blood-brain barrier, potentially improving treatment for recurrent glioblastoma.
What could go wrong
This is a very early pilot study with only 6 participants, so results may not apply to a larger population. The treatment may not improve survival or could cause side effects from the ultrasound or drug.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.